Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate
 in the blood, before and after curative resection of hepatic metastasis of uveal melanoma
 (HMUM) and during post-surgery follow-up
The ct DNA R0 study is a prospective, open labelled, monocentric trial. The aim is to
 evaluate the circulating tumor DNA rate in the blood, before and after curative resection of
 hepatic metastasis of uveal melanoma (HMUM) and during post-surgery follow-up.

 The patient will have a blood sample before and after the surgery and during the post-surgery
 follow-up. The patient will have a maximum of 10 blood samples during the 2 years of his
 follow-up of the study.
Inclusion Criteria:

 1. Aged 18 years old or more

 2. Patient with hepatic injury of metastatic uveal melanoma eligible for curative surgery
 (R0).

 3. No other distant metastasis (CT thoracic -abdomino -pelvic, bone scan).Measurable
 metastatic disease (echography, CT and/or MRI, FDG-PET, (fluoro- D-glucose integrated
 with computed tomography)).

 4. Patient able to stand a blood collection.

 5. Patient explanation given and consent information signed or by legal representative.

 Exclusion Criteria:

 6. Patient without social protection / insurance..

 7. Patient with hepatic metastasis unresectable by surgery

 8. Patient with extra-hepatic metastasis.

 9. Person deprived of liberty or under guardianship

 10. Inability to submit to medical monitoring of the trial for reasons of geography,
 social or psychological.